Vancomycin Dosing for Orbital Cellulitis in Adults

Dosing Recommendations

The Infectious Diseases Society of America recommends initial vancomycin dosing for orbital cellulitis should be 15-20 mg/kg/dose IV every 8-12 hours based on actual body weight, with a maximum of 2 g per dose in patients with normal renal function 4
For severe orbital cellulitis, vancomycin should be continued for 4-6 weeks 5
In critically ill patients with orbital cellulitis, consider a loading dose of 25-30 mg/kg (actual body weight) to rapidly achieve therapeutic levels 4, 5
When administering loading doses, consider prolonging infusion time to 2 hours and using an antihistamine prior to administration to reduce the risk of red man syndrome 4

Trough vancomycin concentrations should be obtained at steady state, prior to the fourth or fifth dose 4
Target trough concentrations of 15-20 μg/mL are recommended for serious infections like orbital cellulitis to ensure adequate tissue penetration 4, 6
Monitoring of peak vancomycin concentrations is not recommended 4
Trough monitoring is especially important in patients who are morbidly obese, have renal dysfunction, or have fluctuating volumes of distribution 4, 6

For isolates with a vancomycin MIC >2 μg/mL, an alternative to vancomycin should be used 7
Some experts recommend the addition of rifampin 600 mg daily or 300-450 mg twice daily to vancomycin for severe infections with central nervous system involvement 8
Alternative agents for orbital cellulitis if vancomycin cannot be used include linezolid 600 mg PO/IV twice daily or trimethoprim-sulfamethoxazole 5 mg/kg/dose IV every 8-12 hours 8
Surgical drainage of contiguous sites of infection or abscess is recommended whenever possible for optimal outcomes 5, 8

The pharmacodynamic parameter that best predicts vancomycin efficacy is the ratio of area under the curve (AUC) to MIC (AUC/MIC) 6
An AUC/MIC >400 is associated with improved clinical response and microbiological eradication 6
Trough concentrations of 15-20 μg/mL generally correlate with achieving the target AUC/MIC ratio 6

Underdosing obese patients when using fixed dosing strategies instead of weight-based dosing 6
Failing to monitor trough levels in patients with serious infections like orbital cellulitis 4
Continuing vancomycin despite lack of clinical response when the isolate has reduced susceptibility 7